Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains

Leah E. Lim, Catherine Vilchèze, Carol Ng, William R. Jacobs, Santiago Ramón-García, Charles J. Thompson

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis. Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment.

Original languageEnglish (US)
Pages (from-to)1040-1046
Number of pages7
JournalAntimicrobial agents and chemotherapy
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2013

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains'. Together they form a unique fingerprint.

  • Cite this